{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:45:42Z","timestamp":1789062342583,"version":"build-2803163510"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Apalutamide is a new drug class, which is approved to treat prostate cancer (PCa). The aim of our study was to assess the safety profiles of apalutamide in real-world through data mining of the United States Food and Drug Administration Adverse Event Reporting System (FAERS).<\/jats:p><jats:p><jats:bold>Method:<\/jats:bold> We included adverse event (AE) reports regarding apalutamide submitted to the FAERS from 2018 quarter 1 (2018Q1) to 2022 quarter 1 (2022Q1). Disproportionality analyses, including reporting odds ratio (ROR), were performed to identify the signals of AEs in patients receiving apalutamide. A signal was detected if the lower limit of the 95% confidence interval (CI) of ROR &amp;gt;1 and at least 3 AEs were reported.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The FAERS database documented 4,156 reports regarding apalutamide from 1 January 2018, to 31 March 2022. A total of 100 significant disproportionality preferred terms (PTs) were retained. Frequently observed AEs in patients receiving apalutamide included rash, fatigue, diarrhea, hot flush, fall, weight decreased, hypertension. The most significant system organ class (SOC) was \u201cskin and subcutaneous tissue disorders\u201d, which mainly consisted of dermatological adverse events (dAEs). The additional AEs observed with the significantly signal contain lichenoid keratosis, increased eosinophil count, bacterial pneumonia, pulmonary tuberculosis, hydronephrosis.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Our findings provide valuable evidence for apalutamide safety profile in the real-world, which could help clinicians and pharmacists to enhance their vigilance and improve the safety of apalutamide in clinical practice.<\/jats:p>","DOI":"10.3389\/fphar.2023.1101861","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T05:22:03Z","timestamp":1685942523000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system"],"prefix":"10.3389","volume":"14","author":[{"given":"Zhihong","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1097\/JU.0000000000001841","article-title":"Apalutamide plus androgen deprivation therapy for metastatic castration-sensitive prostate cancer: Analysis of pain and fatigue in the phase 3 TITAN study","volume":"206","author":"Agarwal","year":"2021","journal-title":"J. Urology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s40265-019-01194-x","article-title":"Apalutamide: A review in non-metastatic castration-resistant prostate cancer","volume":"79","author":"Al-Salama","year":"2019","journal-title":"Drugs"},{"key":"B3","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s40265-018-0900-z","article-title":"Apalutamide: First global approval","volume":"78","author":"Al-Salama","year":"2018","journal-title":"Drugs"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1080\/14656566.2020.1770726","article-title":"An evaluation of apalutamide for the treatment of prostate cancer","volume":"21","author":"Boukovala","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: Final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J. Clin. Oncol. Official J. Am. Soc. Clin. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1158\/0008-5472.CAN-11-3948","article-title":"ARN-509: A novel antiandrogen for prostate cancer treatment","volume":"72","author":"Clegg","year":"2012","journal-title":"Cancer Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: Treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur. Urol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"a030452","DOI":"10.1101\/cshperspect.a030452","article-title":"Androgen signaling in prostate cancer","volume":"7","author":"Dai","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/jnci\/djaa134","article-title":"Inferences about drug safety in Phase\u00a0III trials in oncology: Examples from advanced prostate cancer","volume":"113","author":"Drago","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.2217\/fon-2020-0557","article-title":"Apalutamide for the treatment of metastatic castration-sensitive prostate cancer","volume":"16","author":"Dror","year":"2020","journal-title":"Future Oncol. Lond. Engl."},{"key":"B12","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12904-018-0381-6","article-title":"Quality of life in men with metastatic prostate cancer in their final years before death - a retrospective analysis of prospective data","volume":"17","author":"Holm","year":"2018","journal-title":"BMC Palliat. Care"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1007\/s40265-020-01401-0","article-title":"Apalutamide: A review in metastatic castration-sensitive prostate cancer","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"key":"B14","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1038\/onc.2013.206","article-title":"Prostate cancer progression after androgen deprivation therapy: Mechanisms of castrate resistance and novel therapeutic approaches","volume":"32","author":"Karantanos","year":"2013","journal-title":"Oncogene"},{"key":"B15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.eururo.2018.07.035","article-title":"Managing nonmetastatic castration-resistant prostate cancer","volume":"75","author":"Mateo","year":"2019","journal-title":"Eur. Urol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/JU.0000000000001702","article-title":"Results of a randomized phase II trial of intense androgen deprivation therapy prior to radical prostatectomy in men with high-risk localized prostate cancer","volume":"206","author":"McKay","year":"2021","journal-title":"J. Urology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40261-017-0503-6","article-title":"Can disproportionality analysis of post-marketing case reports be used for comparison of drug safety profiles?","volume":"37","author":"Michel","year":"2017","journal-title":"Clin. Drug Investig."},{"key":"B18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.6004\/jnccn.2019.5011","article-title":"NCCN guidelines updates: Management of prostate cancer","volume":"17","author":"Mohler","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"B19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.urolonc.2020.08.003","article-title":"Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer","volume":"39","author":"Morgans","year":"2021","journal-title":"Urol. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1097\/JU.0000000000002425","article-title":"Dermatological adverse events in prostate cancer patients treated with the androgen receptor inhibitor apalutamide","volume":"207","author":"Pan","year":"2022","journal-title":"J. Urology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4460","DOI":"10.1158\/1078-0432.CCR-20-1041","article-title":"Efficacy and safety exposure-response relationships of apalutamide in patients with nonmetastatic castration-resistant prostate cancer","volume":"26","author":"Perez-Ruixo","year":"2020","journal-title":"Clin. Cancer Res. Official J. Am. Assoc. For Cancer Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1200\/JCO.2013.50.1684","article-title":"Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer","volume":"31","author":"Rathkopf","year":"2013","journal-title":"J. Clin. Oncol. Official J. Am. Soc. Clin. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1080\/14737140.2018.1503954","article-title":"Apalutamide for the treatment of prostate cancer","volume":"18","author":"Rathkopf","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1093\/annonc\/mdx283","article-title":"Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide","volume":"28","author":"Rathkopf","year":"2017","journal-title":"Ann. Oncol. Official J. Eur. Soc. For Med. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S1470-2045(21)00402-2","article-title":"Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): A randomised, placebo-controlled, double-blind, multinational, phase 3 study","volume":"22","author":"Saad","year":"2021","journal-title":"Lancet. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"487","DOI":"10.7150\/ijms.8.487","article-title":"Adverse event profiles of platinum agents: Data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations","volume":"8","author":"Sakaeda","year":"2011","journal-title":"Int. J. Med. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.eururo.2016.04.023","article-title":"Phase 2 study of the safety and antitumor activity of apalutamide (ARN-509), a potent androgen receptor antagonist, in the high-risk nonmetastatic castration-resistant prostate cancer cohort","volume":"70","author":"Smith","year":"2016","journal-title":"Eur. Urol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.eururo.2020.08.011","article-title":"Apalutamide and overall survival in prostate cancer","volume":"79","author":"Smith","year":"2021","journal-title":"Eur. Urol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA a Cancer J. For Clin."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1007\/s10147-019-01526-7","article-title":"An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer","volume":"24","author":"Tsuchiya","year":"2019","journal-title":"Int. J. Clin. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12894-020-00689-0","article-title":"Skin rash following administration of apalutamide in Japanese patients with advanced prostate cancer: An integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study","volume":"20","author":"Uemura","year":"2020","journal-title":"BMC Urol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S1875-5364(13)60035-7","article-title":"Statistical and graphical approaches for disproportionality analysis of spontaneously-reported adverse events in pharmacovigilance","volume":"11","author":"Zink","year":"2013","journal-title":"Chin. J. Nat. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.eururo.2014.09.028","article-title":"The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy","volume":"67","author":"Zumsteg","year":"2015","journal-title":"Eur. Urol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1101861\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T05:22:05Z","timestamp":1685942525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1101861\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,5]]},"references-count":34,"alternative-id":["10.3389\/fphar.2023.1101861"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1101861","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,5]]},"article-number":"1101861"}}